Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Meniere Disease Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Meniere Disease Overview | 7 | 1 |
| Meniere Disease Therapeutics under Development by Companies | 8 | 1 |
| Meniere Disease Pipeline Products Glance | 9 | 4 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Unknown Stage Products | 12 | 1 |
| Meniere Disease Products under Development by Companies | 13 | 1 |
| Meniere Disease Companies Involved in Therapeutics Development | 14 | 5 |
| Orbis Biosciences Inc | 14 | 1 |
| Otonomy, Inc. | 15 | 1 |
| Quark Pharmaceuticals, Inc. | 16 | 1 |
| Sound Pharmaceuticals, Inc. | 17 | 1 |
| Synphora AB | 18 | 1 |
| Meniere Disease Therapeutics Assessment | 19 | 9 |
| Assessment by Monotherapy Products | 19 | 1 |
| Assessment by Target | 20 | 2 |
| Assessment by Mechanism of Action | 22 | 2 |
| Assessment by Route of Administration | 24 | 2 |
| Assessment by Molecule Type | 26 | 2 |
| Drug Profiles | 28 | 10 |
| betamethasone valerate ER Drug Profile | 28 | 1 |
| dexamethasone acetate SR Drug Profile | 29 | 4 |
| latanoprost Drug Profile | 33 | 1 |
| OR-105 Drug Profile | 34 | 1 |
| QPHL-2 Drug Profile | 35 | 1 |
| SPI-1005 Drug Profile | 36 | 2 |
| Meniere Disease Dormant Projects | 38 | 1 |
| Meniere Disease Product Development Milestones | 39 | 8 |
| Featured News &Press Releases | 39 | 1 |
| Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients | 39 | 1 |
| Mar 23, 2016: Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in M ni re s Disease | 39 | 1 |
| Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss | 40 | 1 |
| Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease | 40 | 1 |
| Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting | 41 | 1 |
| Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease | 41 | 1 |
| May 21, 2015: Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere Disease | 41 | 1 |
| Apr 20, 2015: Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere Disease Patients | 42 | 1 |
| Dec 01, 2014: Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere Disease | 43 | 1 |
| Oct 09, 2014: Otonomy Enrolls First Meniere Disease Patients in OTO-104 Multiple-Dose Safety Study | 43 | 1 |
| Dec 11, 2013: Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere Disease | 43 | 1 |
| Sep 29, 2011: Otonomy Presents Positive New Findings From Phase Ib Study Of OTO-104 In Meniere Disease At International Conference | 44 | 1 |
| Apr 28, 2011: Otonomy Announces Positive Results From Phase Ib Study Of OTO-104 In M ni re s Disease | 45 | 2 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |